Immunovant Inc (NASDAQ:IMVT) — Market Cap & Net Worth
Market Cap & Net Worth: Immunovant Inc (IMVT)
Immunovant Inc (NASDAQ:IMVT) has a market capitalization of $7.51 Billion ($7.51 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2759 globally and #992 in its home market, demonstrating a -8.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunovant Inc's stock price $36.38 by its total outstanding shares 206552682 (206.55 Million). Also see balance sheet size of Immunovant Inc for a full breakdown of the balance sheet.
Immunovant Inc Market Cap History: 2019 to 2026
Immunovant Inc's market capitalization history from 2019 to 2026. Data shows growth from $3.28 Billion to $7.51 Billion (19.60% CAGR). Also see cash efficiency ratio of Immunovant Inc for how efficiently the company converts equity into cash flow.
Index Memberships
Immunovant Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.28% | #66 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.02% | #313 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.40% | #46 of 263 |
Weight: Immunovant Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immunovant Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunovant Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Immunovant Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of IMVT by Market Capitalization
Companies near Immunovant Inc in the global market cap rankings as of September 18, 2026. Review Immunovant Inc (IMVT) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Immunovant Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Immunovant Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Immunovant Inc's market cap moved from $3.28 Billion to $ 7.51 Billion, with a yearly change of 19.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.51 Billion | +43.12% |
| 2025 | $5.25 Billion | +2.62% |
| 2024 | $5.12 Billion | -41.21% |
| 2023 | $8.70 Billion | +137.35% |
| 2022 | $3.67 Billion | +108.33% |
| 2021 | $1.76 Billion | -81.55% |
| 2020 | $9.54 Billion | +191.05% |
| 2019 | $3.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Immunovant Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.51 Billion USD |
| MoneyControl | $7.51 Billion USD |
| MarketWatch | $7.51 Billion USD |
| marketcap.company | $7.51 Billion USD |
| Reuters | $7.51 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinat… Read more